Skip to content

Zaleplon

    DEA Class;  Rx

    Common Brand Names; Sonata

    • Sedative/Hypnotics; 

    Short-acting non-benzodiazepine hypnotic.
    More rapid onset than zolpidem; short half-life reduces “hangover” effects; does not cause early-AM awakening; anticonvulsant, anxiolytic, and myorelaxant effects more likely with higher doses.
    Used for treatment of insomnia.

    Indicated for the short-term (generally 7 to 10 days) treatment of insomnia.

    Hypersensitivity

    Patients who have experienced complex sleep behaviors after taking zaleplon

    • Headache (38%)
    • Dizziness (7-9%)
    • Nausea (6-8%)
    • Abdominal pain (6%)
    • Weakness (5-7%)
    • Dysmenorrhea (3-4%)
    • Eye pain (3-4%)
    • Amnesia (2-4%)
    • Parasthesia (3%)
    • Tremor (2%)
    • Fever
    • Photosensitivity
    • Anorexia
    • Colitis
    • Periphipheral edema
    • Amnesia
    • Anxiety
    • Depersonalization
    • Hallucination
    • Hypesthesia
    • Vertigo
    • Epistaxis
    • Abnl vision
    • Ear pain
    • Hyperacusis
    • Parosmia

    Use caution in mild-to-moderate hepatic impairment; not recommended with severe hepatic impairment

    Amnesia may occur

    Use caution in patients respiratory diseases or patients experiencing clinical depression (condition may worsen)

    Therapy can cause drowsiness and a decreased level of consciousness; patients, particularly the elderly, are at higher risk of falls

    In primarily depressed patients treated with sedative-hypnotics, worsening of depression, including suicidal thoughts and actions (including completed suicides), reported

    Post-marketing reports have shown complex sleep behaviors may occur with drug alone at recommended dosages, with or without the concomitant use of alcohol or other central nervous system (CNS) depressants

    Dosage adjustments of drug and of other concomitant CNS depressants may be necessary when drug administered with such agents because of potentially additive effects

    Use with other sedative-hypnotics at bedtime or the middle of the night not recommended

    Risk of next-day psychomotor impairment, including impaired driving, is increased if drug taken with less than a full night of sleep remaining (7 to 8 hours); if a higher than recommended dose taken; if coadministered with other CNS depressants or alcohol; or if coadministered with other drugs that increase blood levels of zaleplon; warn patients against driving and other activities requiring complete mental alertness if drug taken in these circumstances

    Signs and symptoms associated with withdrawal from other CNS depressant drugs reported following rapid dose decrease or abrupt discontinuation of use of sedative/hypnotics

    Pregnancy Category: C

    Lactation: small amount secreted in breast milk, not recommended

    Adults

    20 mg/day PO at bedtime. Debilitated adult patients may require 10 mg/day PO.

    Geriatric

    10 mg/day PO at bedtime.

    Adolescents

    Safety and efficacy have not been established.

    Children

    Safety and efficacy have not been established.

    Infants

    Not indicated.

    Zaleplon

    capsule: Schedule IV

    • 5mg
    • 10mg